SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).

被引：5
|
作者：
Chi, K. N.
De Bono, J. S.
Higano, C. S.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Hosp, Sutton, Surrey, England
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS180
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Tu, D.
    Eigl, B.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Bevacizumab andWeekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
    Francini, Filippo
    Pascucci, Alessandra
    Francini, Edoardo
    Bargagli, Gianluca
    Conca, Raffaele
    Licchetta, Antonella
    Roviello, Giandomenico
    Martellucci, Ignazio
    Chiriaco, Giorgio
    Miano, Salvatora Tindara
    Marzocca, Giuseppe
    Manganelli, Antonio
    Ponchietti, Roberto
    Savelli, Vinno
    Petrioli, Roberto
    PROSTATE CANCER, 2011, 2011
  • [34] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [35] A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Small, Eric Jay
    Lance, Raymond S.
    Redfern, Charles H.
    Millard, Frederick E.
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Dawson, Nancy Ann
    McCoy, Candice
    Stubbs, Andrew
    DeVries, Todd
    dela Rosa, Corazon P.
    Sheikh, Nadeem A.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Phase I/II trial to establish the safety and preliminary efficacy of the combination of docetaxel, prednisone, and SOM 230 in metastatic castrate-resistant prostate cancer (CRPC).
    Vankayala, H. M.
    Heilbrun, L. K.
    Fontana, J. A.
    Vaishampayan, U. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.
    Buonerba, Carlo
    Grillone, Francesco
    Rossetti, Sabrina
    Livi, Lorenzo
    Scartozzi, Mario
    Tagliaferri, Pierosandro
    Bruzzese, Dario
    Scafuri, Luca
    Riccio, Vittorio
    Costabile, Ferdinando
    Bosso, Davide
    Iaccarino, Simona
    Facchini, Gaetano
    Carrano, Simone
    Izzo, Michela
    Caraglia, Michele
    De Placido, Sabino
    di Lorenzo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] Phase III SYNERGY trial: Docetaxel ± custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent A.
    Reeves, James Andrew
    Feyerabend, Susan
    Gravis, Gwenaelle
    Ferrero, Jean-Marc
    Jacobs, Cindy
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)
    de Bono, J.
    Bracarda, S.
    Chi, K.
    Massard, C.
    Olmos Hidalgo, D.
    Sandhu, S.
    Sternberg, C. N.
    Gendreau, S.
    Xu, N.
    Baney, T.
    Maslyar, D.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] βIII-tubulin expression as a predictor of docetaxel resistance in metastatic castrate-resistant prostate cancer
    Sanchez, Bertha E.
    Gupta, Nilesh
    Mahan, Meredith
    Barrack, Evelyn R.
    Reddy, Prem-veer
    Hwang, Clara
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345